PDS Biotechnology Corporation

5.21 USD
-0.04 (-0.76%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

PDS Biotechnology Corporation stock is up 14.51% since 30 days ago. The next earnings date is Mar 26, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 December’s closed higher than November. In the last 3 Unusual Options Trades, there were 3 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
10 Nov 15:52 19 Jan, 2024 7.50 CALL 150 1376
10 Nov 18:47 19 Jan, 2024 2.50 CALL 150 532
14 Nov 15:14 17 May, 2024 5.00 CALL 100 83

About PDS Biotechnology Corporation

PDS Biotechnology Corporation focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials.